{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:26:07Z","timestamp":1789500367486,"version":"build-2803163510"},"reference-count":30,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Long-term follow-up after transcatheter aortic valve replacement (TAVR) is of interest given that longitudinal data on mortality and durability of transcatheter heart valves are limited. The REPRISE III (Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System\u2014Randomized Clinical Evaluation) randomized clinical trial compared the mechanically expanded Lotus valve with the self-expanding CoreValve\/EvolutR TAVR platforms.<\/jats:p><\/jats:sec>Objective<\/jats:title>To describe the final 5-year outcomes of the REPRISE III trial.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This prespecified secondary analysis assessed the final 5-year clinical, functional, and echocardiographic outcomes of 912 patients from the REPRISE III trial, which was conducted at 55 centers in North America, Europe, and Australia between September 22, 2014, and December 24, 2015. Patients had high risk for aortic stenosis or severe or symptomatic aortic stenosis. Data were analyzed from September 22, 2014, to May 21, 2021.<\/jats:p><\/jats:sec>Intervention<\/jats:title>Lotus valve or CoreValve\/EvolutR TAVR platforms.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Valve Academic Research Consortium-2 end points, hemodynamic measures, functional status, and health status were examined through the 5-year follow-up.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 912 patients (mean [SD] age, 82.8 [7.3] years; 463 women [50.8%]) were randomized to either the Lotus valve group (n\u2009=\u2009607) or CoreValve\/EvolutR group (n\u2009=\u2009305), with a baseline Society of Thoracic Surgeons risk score of 6.8%. Clinical follow-up data from the REPRISE III trial were available for 581 patients (95.7%) in the Lotus valve group and 285 patients (93.4%) in the CoreValve\/EvolutR group. At 5 years, the cumulative event rate for all-cause mortality was 50.9% in the Lotus valve group vs 52.8% in the CoreValve\/EvolutR group (P<\/jats:italic>\u2009=\u2009.59). Disabling stroke was less frequent with the Lotus valve vs CoreValve\/EvolutR (cumulative event rates, 8.3% vs 12.2%; P<\/jats:italic>\u2009=\u2009.04), whereas the cumulative event rates for overall stroke were similar in both groups (14.1% vs 15.3%; P<\/jats:italic>\u2009=\u2009.38). Insertion of a new permanent pacemaker (38.9% vs 27.3%; P<\/jats:italic>\u2009&amp;lt;\u2009.001) and detection of prosthetic aortic valve thrombosis (5.8% vs 1.8%; P<\/jats:italic>\u2009=\u2009.007) were more common in the Lotus valve group than in the CoreValve\/EvolutR group. A smaller proportion of patients who received the Lotus valve experienced valve malpositioning (0% vs 2.6%; P<\/jats:italic>\u2009&amp;lt;\u2009.001) and required the use of a second valve (1.0% vs 3.8%; P<\/jats:italic>\u2009&amp;lt;\u2009.001) during the procedure compared with those who received the CoreValve\/EvolutR. Compared with the Lotus valve group, the CoreValve\/EvolutR group had a significantly lower mean (SD) aortic gradient (7.8 [4.2] mm Hg vs 12.6 [6.7] mm Hg; P<\/jats:italic>\u2009&amp;lt;\u2009.001) and larger valve areas (1.57 [0.56] cm2<\/jats:sup> vs 1.42 [0.42] cm2<\/jats:sup>; P<\/jats:italic>\u2009=\u2009.10). After 5 years, the proportion of patients with moderate or greater paravalvular leak was not significantly higher with the CoreValve\/EvolutR than with the Lotus valve (1.9% vs 0%; P<\/jats:italic>\u2009=\u2009.31); however, the proportion of patients with mild paravalvular leak was higher in the CoreValve\/EvolutR group compared with the Lotus valve group (23.1% vs 7.8%; P<\/jats:italic>\u2009=\u2009.006). Long-term, similar improvements in New York Heart Association class and Kansas City Cardiomyopathy Questionnaire score were observed in both groups.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The REPRISE III trial found that, at 5 years, the clinical outcomes of the Lotus valve were comparable to those of the CoreValve\/EvolutR and that the Lotus valve was safe and effective.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT02202434<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.38792","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T15:09:16Z","timestamp":1666883356000},"page":"e2238792","source":"Crossref","is-referenced-by-count":8,"title":["Long-term Outcomes of Transcatheter Aortic Valve Replacement With the Lotus Valve vs CoreValve\/EvolutR"],"prefix":"10.1001","volume":"5","author":[{"given":"David G.","family":"Rizik","sequence":"first","affiliation":[{"name":"Department of Cardiology, HonorHealth and the Scottsdale-Lincoln Health Network, Scottsdale, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Rajagopal","sequence":"additional","affiliation":[{"name":"Cardiology Department, Piedmont Hospital, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj R.","family":"Makkar","sequence":"additional","affiliation":[{"name":"Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanvir","family":"Bajwa","sequence":"additional","affiliation":[{"name":"Department of Medicine, Aurora St Luke's Medical Center, Milwaukee, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal S.","family":"Kleiman","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Linke","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Cardiology, Technische Universit\u00e4t Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean J.","family":"Kereiakes","sequence":"additional","affiliation":[{"name":"The Christ Hospital Heart and Vascular Center\/The Lindner Research Center Cincinnati, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Waksman","sequence":"additional","affiliation":[{"name":"Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod H.","family":"Thourani","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Marcus Valve Center, Piedmont Heart Institute, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Stoler","sequence":"additional","affiliation":[{"name":"Baylor Heart & Vascular Hospital, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Mishkel","sequence":"additional","affiliation":[{"name":"Division of Cardiology, NorthShore University HealthSystem, University of Chicago Pritzker School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay S.","family":"Iyer","sequence":"additional","affiliation":[{"name":"Gates Vascular Institute, Interventional Cardiology, University at Buffalo, School of Medicine and Biomedical Sciences, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Buchbinder","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Foundation for Cardiovascular Medicine, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"G\u00f6tberg","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Clinical Sciences, Lund University, Skane University Hospital, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Bjursten","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, Sk\u00e5ne University Hospital, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic J.","family":"Allocco","sequence":"additional","affiliation":[{"name":"Boston Scientific Corp, Marlborough, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Reardon","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"issue":"24","key":"zoi221100r1","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1161\/01.CIR.0000047200.36165.B8","article-title":"Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description.","volume":"106","author":"Cribier","year":"2002","journal-title":"Circulation"},{"issue":"23","key":"zoi221100r2","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa1103510","article-title":"Transcatheter versus surgical aortic-valve replacement in high-risk patients.","volume":"364","author":"Smith","year":"2011","journal-title":"N Engl J Med"},{"issue":"19","key":"zoi221100r3","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1056\/NEJMoa1400590","article-title":"Transcatheter aortic-valve replacement with a self-expanding prosthesis.","volume":"370","author":"Adams","year":"2014","journal-title":"N Engl J Med"},{"issue":"17","key":"zoi221100r4","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1514616","article-title":"Transcatheter or surgical aortic-valve replacement in intermediate-risk patients.","volume":"374","author":"Leon","year":"2016","journal-title":"N Engl J Med"},{"issue":"14","key":"zoi221100r5","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1700456","article-title":"Surgical or transcatheter aortic-valve replacement in intermediate-risk patients.","volume":"376","author":"Reardon","year":"2017","journal-title":"N Engl J Med"},{"issue":"18","key":"zoi221100r6","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMoa1814052","article-title":"Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients.","volume":"380","author":"Mack","year":"2019","journal-title":"N Engl J Med"},{"issue":"18","key":"zoi221100r7","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1056\/NEJMoa1816885","article-title":"Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients.","volume":"380","author":"Popma","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi221100r8","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1910555","article-title":"Five-year outcomes of transcatheter or surgical aortic-valve replacement.","volume":"382","author":"Makkar","year":"2020","journal-title":"N Engl J Med"},{"issue":"22","key":"zoi221100r9","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1016\/j.jacc.2018.08.2146","article-title":"5-year outcomes of self-expanding transcatheter versus surgical aortic valve replacement in high-risk patients.","volume":"72","author":"Gleason","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"zoi221100r10","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/j.jacc.2020.09.595","article-title":"STS-ACC TVT registry of transcatheter aortic valve replacement.","volume":"76","author":"Carroll","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"zoi221100r11","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1016\/j.jtcvs.2021.04.002","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"162","author":"Otto","year":"2021","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"1","key":"zoi221100r12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1001\/jama.2017.19132","article-title":"Effect of mechanically expanded vs self-expanding transcatheter aortic valve replacement on mortality and major adverse clinical events in high-risk patients with aortic stenosis: the REPRISE III randomized clinical trial.","volume":"319","author":"Feldman","year":"2018","journal-title":"JAMA"},{"issue":"3","key":"zoi221100r13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1001\/jamacardio.2019.0091","article-title":"Two-year outcomes after transcatheter aortic valve replacement with mechanical vs self-expanding valves: the REPRISE III randomized clinical trial.","volume":"4","author":"Reardon","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"24","key":"zoi221100r14","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1161\/CIRCULATIONAHA.118.034129","article-title":"Hemodynamic and echocardiographic comparison of the Lotus and CoreValve transcatheter aortic valves in patients with high and extreme surgical risk: an analysis from the REPRISE III randomized controlled trial.","volume":"137","author":"Asch","year":"2018","journal-title":"Circulation"},{"issue":"15","key":"zoi221100r15","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.jacc.2012.09.001","article-title":"Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document.","volume":"60","author":"Kappetein","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"zoi221100r16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jacc.2010.12.005","article-title":"Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium.","volume":"57","author":"Leon","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"zoi221100r17","doi-asserted-by":"publisher","first-page":"Q70","DOI":"10.4244\/EIJV8SQA12","article-title":"Boston Scientific Lotus valve.","volume":"8","author":"Meredith","year":"2012","journal-title":"EuroIntervention"},{"issue":"11","key":"zoi221100r18","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.4244\/EIJV9I11A216","article-title":"Transfemoral aortic valve replacement with the repositionable Lotus valve system in high surgical risk patients: the REPRISE I study.","volume":"9","author":"Meredith","year":"2014","journal-title":"EuroIntervention"},{"issue":"12","key":"zoi221100r19","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.amjcard.2017.08.049","article-title":"Comparison of 1-year survival and frequency of paravalvular leakage using the Sapien 3 versus the Sapien XT for transcatheter aortic valve implantation for aortic stenosis.","volume":"120","author":"Meyer","year":"2017","journal-title":"Am J Cardiol"},{"issue":"5","key":"zoi221100r20","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ccd.v97.5","article-title":"Effect of a fourth-generation transcatheter valve enhanced skirt on paravalvular leak.","volume":"97","author":"Welle","year":"2021","journal-title":"Catheter Cardiovasc Interv"},{"issue":"2","key":"zoi221100r21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jcin.2019.08.035","article-title":"Three generations of self-expanding transcatheter aortic valves: a report from the STS\/ACC TVT registry.","volume":"13","author":"Forrest","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"issue":"24","key":"zoi221100r22","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1016\/j.jcin.2021.09.019","article-title":"Subclinical leaflet thrombosis after transcatheter aortic valve replacement: a meta-analysis.","volume":"14","author":"Bogyi","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"issue":"7","key":"zoi221100r23","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1002\/ccd.v92.7","article-title":"The prevalence of computed tomography-defined leaflet thrombosis in intra- versus supra-annular transcatheter aortic valve prostheses.","volume":"92","author":"Rashid","year":"2018","journal-title":"Catheter Cardiovasc Interv"},{"issue":"15","key":"zoi221100r24","doi-asserted-by":"publisher","first-page":"e1748","DOI":"10.4244\/EIJ-D-17-01062","article-title":"Bioprosthetic aortic valve leaflet thrombosis detected by multidetector computed tomography is associated with adverse cerebrovascular events: a meta-analysis of observational studies.","volume":"13","author":"Rashid","year":"2018","journal-title":"EuroIntervention"},{"issue":"16","key":"zoi221100r25","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.4244\/EIJ-D-18-00779","article-title":"Long-term results and durability of the CoreValve transcatheter aortic bioprosthesis: outcomes beyond five years.","volume":"14","author":"Panico","year":"2019","journal-title":"EuroIntervention"},{"key":"zoi221100r26","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2022.2695","article-title":"Self-expanding transcatheter vs surgical aortic valve replacement in intermediate-risk patients: 5-year outcomes of the SURTAVI randomized clinical trial.","author":"Van Mieghem","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"9","key":"zoi221100r27","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.jcin.2019.12.026","article-title":"5-year outcomes after TAVR with balloon-expandable versus self-expanding valves: results from the CHOICE randomized clinical trial.","volume":"13","author":"Abdel-Wahab","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"issue":"8","key":"zoi221100r28","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.jcin.2015.03.024","article-title":"5-year outcomes after transcatheter aortic valve implantation with CoreValve prosthesis.","volume":"8","author":"Barbanti","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"issue":"24","key":"zoi221100r29","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1161\/CIRCULATIONAHA.118.036606","article-title":"Five-year clinical and echocardiographic outcomes from the Nordic Aortic Valve Intervention (NOTION) randomized clinical trial in lower surgical risk patients.","volume":"139","author":"Thyregod","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"zoi221100r30","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1093\/icvts\/ivy190","article-title":"Supra-annular versus intra-annular prostheses in aortic valve replacement: impact on haemodynamics and clinical outcomes.","volume":"28","author":"Kim","year":"2019","journal-title":"Interact Cardiovasc Thorac Surg"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2797783\/rizik_2022_oi_221100_1666195591.94718.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T15:09:18Z","timestamp":1666883358000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2797783"}},"subtitle":["A Secondary Analysis of the REPRISE III Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.38792","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,27]]}}}